Skip to main content


Bladder cancer

Bladder Cancer

Bladder Cancer

Oncology - Bladder Cancer

As the fifth most common cancer in Europe, bladder cancer affects hundreds of thousands of people. We’re dedicated to helping patients and their loved ones find hope and relief, through improving targeted therapies and deepening our understanding of this complex disease.

Our understanding of bladder cancer


In Europe, bladder cancer is the 5th most common cancer and it is estimated that by the year 2030, around 219,000 people will be diagnosed across Europe each year.[1][2]

People living with the disease often face poor outcomes, with a 5% survival rate over five years for metastatic settings.[3] This means there is a high unmet need for new treatment options in this space.[1] At Janssen we are embracing this challenge.

There is strong scientific evidence to show that the earlier the diagnosis of bladder cancer, the better the prognosis is for patients.[4]

We are focusing on better understanding the drivers of urothelial cancer, the most common type of bladder cancer,[5] and we are exploring targeted therapies – alone and in combination – to improve patients’ expected outcomes as a result of their treatment.

cancer cell in 3D

Bladder cancer in numbers


• Bladder cancer incidence is approximately 5x more in men than in women.[10]

• 9 out of 10 people are over the age of 55 when they are diagnosed.[8]


• Urothelial carcinoma is 5th most common cancer in Europe[6] and the most common type of bladder cancer.[5]

• 150,000 new cases diagnosed each year.[7]


• Since the mid- to late- 1990s, bladder cancer mortality has declined in many regions of Europe, with the exception of some central, Southern, and Eastern European, and Baltic countries.[11]

• About 65,000 deaths from bladder cancer in Europe in 2018.[9]

Delivering individual patient victories through precision oncology

We see enormous potential in the use of companion diagnostics to help identify patients who are most likely to respond to a therapy, and thereby achieve the best outcomes.

As part of this effort, we are exploring the role of fibroblast growth factor receptor (FGFR) predictive biomarkers to guide targeted, personalised treatment decisions for in tumor-agnostic settings.

For decades, our simplistic equipment and methods used in the management of urothelial cancer yielded stagnant mortality rates. Recent research efforts in the field of precision oncology have provided key insights that have transformed the treatment paradigm, and will undoubtedly continue to expand our therapeutic options in the years to come.[12]

Evidence suggests that the FGFR pathway may provide another option for treating bladder cancer.[13]

Current phase 3 trials are ongoing to demonstrate whether FGFR inhibitors improve outcomes over standard of care in FGFR3-altered metastatic urothelial carcinoma.[14]

Our collaborations


We are dedicated to collaborating with partners across the globe who share our vision of making cancer a chronic, manageable condition and ultimately a curable disease. Based on the belief that collaborations are an essential part driving change and innovation, we’re looking to engage in strategic partnerships that bring fresh approaches to understanding, preventing and treating bladder cancer.


TARIS acquisition

We’re very excited about the opportunity to advance the science of genitourinary cancers and improve the care of patients diagnosed with bladder cancer through our acquisition of TARIS Biomedical LLC in 2019.[15] TARIS technology advances the ability and the expertise we have to address bladder cancer treatment for growing populations of patients.

The TARIS system is a first-in-class clinical platform, which delivers therapeutics locally to patients diagnosed with bladder cancer (and potentially other types of cancer). The silicone-based delivery device allows for the continuous release of medication directly to tumours located in the bladder. We believe that the TARIS bladder-specific drug-delivery platform has the potential to be transformative in delivering active treatments locally, and has the ability to be combined with systemic therapies to develop curative regimens for early stage non-muscle and muscle invasive bladder cancer patients.

Find out more

Collaborate with us

Janssen Oncology is committed to ensuring success in our collaborations. Our Johnson & Johnson Innovation and Janssen Business Development teams bring scientific and commercial expertise, while our flexible structure enables us to work effectively with a variety of partners to create the best business model for each collaboration.

We look for collaborations in which each partner brings unique strengths and experiences, so that together we can achieve more than either could alone.

learn more

back to oncology